Publications & Patents
Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines G.W. Stone et al., J Virol 80:1762-1772, 2006.
Design of CD40 Agonists and their use in growing B cells for cancer immunotherapy. R.S. Kornbluth, M. Stempniak, G.W. Stone. Int Rev Immunol 31(4):279-288, 2012.
Vaccination with a fusion protein that introduces HIV-1 Gag antigen into a multi-trimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-Gag S.Gupta et al. J Virol 88:1492-1501, 2014.
FortiVac issued patents, expiring 03/16/2034
Corresponding patents have issued at EPO, Canada, Spain, Australia, Denmark, Poland, and elsewhere